Arthritis & Rheumatic Disease Specialties | Aventura, FL

Research site

(Unclaimed)

Location

2801 North East 213th Street Suite 801, Aventura, Florida, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

BIIB059

Litifilimab

ABBV-599

Leronlimab

Macitentan

GLPG3667

BMS-986165

Adalimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 26 total trials

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting

Psoriatic Arthritis

Biological: Placebo

Biological: Risankizumab

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting

Psoriatic Arthritis (PsA)

Biological: Placebo

Biological: Risankizumab

A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus (GALACELA)

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling

Systemic Lupus Erythematosus

Drug: GLPG3667

Drug: Placebo

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (SELECT-AXIS 2)

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.The main objectives o...

Active, not recruiting

Spondyloarthritis

Drug: Placebo

Drug: Upadacitinib

Locations recently updated

A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD)

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-1)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Litifilimab

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus...

Active, not recruiting

Systemic Lupus Erythematosus

Drug: BMS-986165

Locations recently updated

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling

Rheumatoid Arthritis

Drug: Adalimumab

Drug: Upadacitinib

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (EURELIA2)

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling

Hyperuricemia

Tophi

Drug: Allopurinol

Drug: Tigulixostat

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis (RESET-RA)

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting

Rheumatoid Arthritis

Procedure: Implant Procedure

Device: Non-active stimulation